16-56519765-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM1PM2PP3_ModeratePP5
The NM_031885.5(BBS2):c.98C>A(p.Ala33Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,613,096 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. A33A) has been classified as Likely benign.
Frequency
Consequence
NM_031885.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BBS2 | NM_031885.5 | c.98C>A | p.Ala33Asp | missense_variant | 1/17 | ENST00000245157.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BBS2 | ENST00000245157.11 | c.98C>A | p.Ala33Asp | missense_variant | 1/17 | 1 | NM_031885.5 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152234Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000805 AC: 2AN: 248348Hom.: 0 AF XY: 0.00000742 AC XY: 1AN XY: 134842
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1460862Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 726724
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152234Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74374
ClinVar
Submissions by phenotype
Bardet-Biedl syndrome 2 Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Oct 01, 2021 | PM2, PP3, PP4, PP5 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 15, 2021 | NM_031885.3(BBS2):c.98C>A(A33D) is a missense variant classified as a variant of uncertain significance in the context of Bardet-Biedl syndrome, BBS2-related. A33D has not been observed in cases with relevant disease. Functional assessments of this variant are not available in the literature. A33D has been observed in population frequency databases (gnomAD: AMR 0.003%). In summary, there is insufficient evidence to classify NM_031885.3(BBS2):c.98C>A(A33D) as pathogenic or benign. Please note: this variant was assessed in the context of healthy population screening. - |
Retinitis pigmentosa 74 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2015 | - - |
Bardet-Biedl syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jul 29, 2023 | This sequence change replaces alanine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 33 of the BBS2 protein (p.Ala33Asp). This variant is present in population databases (rs797045155, gnomAD 0.003%). This missense change has been observed in individual(s) with Bardet-Biedl syndrome and/or nonsyndromic retinitis pigmentosa (PMID: 25541840; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 209042). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BBS2 protein function. For these reasons, this variant has been classified as Pathogenic. - |
Retinitis pigmentosa Pathogenic:1
Likely pathogenic, no assertion criteria provided | research | Sharon lab, Hadassah-Hebrew University Medical Center | Jun 23, 2019 | - - |
BBS2-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 01, 2024 | The BBS2 c.98C>A variant is predicted to result in the amino acid substitution p.Ala33Asp. This variant was reported in the compound heterozygous state in three siblings who presented with retinitis pigmentosa (Shevach et al. 2015. PubMed ID: 25541840). This variant was also described in the apparently homozygous state in at least two other individuals with retinitis pigmentosa or suspected Bardet-Biedl syndrome; however, additional clinical and familial details were not provided (Sharon et al. 2019. PubMed ID: 31456290, supplementary data; Marinakis et al. 2021. PubMed ID: 34008892). This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at